Real-world prevalence of potential drug–drug interactions associated with oral advanced therapies indicated for ulcerative colitis
Comorbidities and polypharmacy among patients with UC pose a high risk of DDIs for oral advanced therapies and required pre-treatment clinical assessments can be complicated. This justifies a thorough review of patient profiles for prescribers considering novel treatment options.
Authors
- Todor I. Totev (ORCID: https://orcid.org/0000-0003-0253-325X)
- Sabree Burbage
- Maryia Zhdanava (ORCID: https://orcid.org/0000-0002-7995-2578)
- Sumesh Kachroo (ORCID: https://orcid.org/0000-0002-7190-6323)
- Patrick Lefèbvre (ORCID: https://orcid.org/0000-0002-2216-5442)
- Lilián Díaz (ORCID: https://orcid.org/0009-0006-6397-0129)
- Dominic Pilon
- Bridget Godwin
Institutions
- Janssen (Belgium) (BE)
- Johnson & Johnson (Israel) (IL)
- Janssen Scientific Affairs (United States)
Publication Details
- Journal
- Current Medical Research and Opinion
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1080/03007995.2025.2465649
- Primary Topic
- Microscopic Colitis
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Janssen Scientific Affairs